肺炎球菌ワクチンの世界市場レポート 2024年

肺炎球菌ワクチンの市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には5.9%の年間複合成長率（CAGR）で113億6,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、肺炎球菌株の進化、進行中の研究開発努力、予防接種の優先順位付け、ワクチンへのアクセスの拡大、人口の高齢化などの要因に起因すると考えられます。予測期間における注目すべき動向には、多価ワクチンの開発、リスクのあるグループへの標的型ワクチン接種、ワクチンの有効性を高める取り組み、教育と啓発キャンペーン、乳児の予防接種への焦点が含まれます。

肺炎球菌ワクチン市場の成長は、肺炎球菌汚染の蔓延の増加によって促進されると予想されます。肺炎球菌汚染には、肺炎球菌または肺炎球菌によって引き起こされるさまざまな感染症が含まれ、肺炎、血流感染症、耳感染症、副鼻腔感染症などの症状を引き起こします。 肺炎球菌ワクチンは、抗体の生成を刺激する上で重要な役割を果たし、肺炎球菌に対する保護を提供します。これは、子供、高齢者、免疫力が低下している人など、脆弱な集団にとって特に重要です。たとえば、2022年1月に疾病管理予防センター（CDC）が発表した最近のデータでは、米国では肺炎球菌性肺炎により年間約15万人が入院しており、成人市中肺炎症例のかなりの部分を占めていることが明らかになった。

肺炎球菌ワクチン市場の成長は、高齢化人口の増加によってさらに促進されています。人口情勢が高齢化に向かうにつれて、高齢者の割合が顕著に増加しています。肺炎球菌性疾患、特に肺炎は、加齢に伴う免疫系の低下により、高齢者でより蔓延し、重症化する傾向があります。世界保健機関（WHO）の2022年10月のデータによると、60歳以上の世界人口は2020年の10億人から2030年には14億人に増加すると予想されており、高齢者の肺炎球菌感染症に対する脆弱性が高まっていることが浮き彫りとなっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の肺炎球菌ワクチン市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の肺炎球菌ワクチン市場規模実績と成長、2018～2023年
• 世界の肺炎球菌ワクチン市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の肺炎球菌ワクチン市場、製品タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• プレブナー13
• シンフロリックス
• ニューモバックス23
• その他
• 世界の肺炎球菌ワクチン市場、投与経路別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 静脈内
• 筋肉内
• 皮下
• 世界の肺炎球菌ワクチン市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 薬局
• 地域クリニック
• 公衆衛生機関
• その他
• 世界の肺炎球菌ワクチン市場、エンドユーザー別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 小児
• 成人

第7章 地域と国の分析

• 世界の肺炎球菌ワクチン市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界の肺炎球菌ワクチン市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 肺炎球菌ワクチン市場の競合情勢
• 肺炎球菌ワクチン市場の企業プロファイル
  • Pfizer Inc.
  • Johnson &Johnson
  • Merck &Co. Inc.
  • Novartis International AG
  • Sanofi SA

第31章 その他の大手と革新的な企業

• AstraZeneca plc
• GlaxoSmithKline plc
• Eli Lilly and Company
• Astellas Pharma Inc.
• CSL Limited
• Anhui Zhifei Longcom Biopharmaceutical Co. Ltd
• Serum Institute of India Private Limited
• Emergent BioSolutions Inc.
• Walvax Biotechnology Co. Ltd
• Biological E Limited
• Hualan Biological Engineering Inc.
• Valneva SE
• Beijing Minhai Biotechnology Limited Company
• NPO Petrovax Pharm LLC
• Vaxcyte Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

The pneumococcal vaccine is a vaccination designed to provide protection against severe pneumococcal infections caused by Streptococcus pneumoniae bacteria, including pneumonia, meningitis, and sepsis. It is particularly effective in preventing one of the most common causes of meningitis and other illnesses in infants, such as acute ear infections.

The primary pneumococcal vaccines include Prevnar 13, Synflorix, Pneumovax23, and others. Prevnar 13 is a pneumococcal conjugate vaccine containing 13 distinct strains of Streptococcus pneumoniae. It is administered to children and tested on immunocompromised patients to prevent pneumococcal disease. The vaccine can be administered through intravenous, intramuscular, and subcutaneous routes and is distributed through pharmacies, community clinics, public health agencies, and other channels to end-users such as pediatrics and adults.

The pneumococcal vaccine market research report is one of a series of new reports from The Business Research Company that provides pneumococcal vaccine market statistics, including pneumococcal vaccine industry global market size, regional shares, competitors with a pneumococcal vaccine market share, detailed pneumococcal vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the pneumococcal vaccine industry. This pneumococcal vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pneumococcal vaccine market size has grown strongly in recent years. It will grow from $8.47 billion in 2023 to $9.04 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%. The growth observed in the historical period can be attributed to factors such as the discovery of Streptococcus pneumoniae, increasing public health concerns related to pneumococcal infections, early efforts in vaccination, advancements in healthcare, and changes in vaccine policies.

The pneumococcal vaccine market size is expected to see strong growth in the next few years. It will grow to $11.36 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The anticipated growth in the forecast period can be attributed to factors such as the evolution of pneumococcal strains, ongoing research and development efforts, prioritization of immunization, expanded access to vaccines, and an aging population. Noteworthy trends in the forecast period include the development of multivalent vaccines, targeted vaccination in at-risk groups, efforts to enhance vaccine efficacy, educational and awareness campaigns, and a focus on infant immunization.

The growth of the pneumococcal vaccine market is anticipated to be driven by the increasing prevalence of pneumococcal contamination. Pneumococcal contamination encompasses various infections caused by Streptococcus pneumoniae or pneumococcus bacteria, leading to conditions such as pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine plays a crucial role in stimulating the production of antibodies, offering protection against pneumococcal bacteria. This is particularly vital for vulnerable populations, including children, the elderly, and individuals with weakened immune systems. For instance, recent data from the Center for Disease Control and Prevention (CDC) in January 2022 revealed that pneumococcal pneumonia results in approximately 150,000 hospitalizations annually in the United States, representing a substantial portion of adult community-acquired pneumonia cases.

The growth of the pneumococcal vaccine market is further propelled by the significant contribution of the growing aging population. As the demographic landscape shifts towards an aging population, there is a notable increase in the proportion of elderly individuals. Pneumococcal diseases, especially pneumonia, tend to be more prevalent and severe in older adults due to age-related weakening of the immune system. According to October 2022 data from the World Health Organization (WHO), the global population aged 60 or above is expected to rise from 1 billion in 2020 to 1.4 billion in 2030, highlighting the increasing vulnerability of older individuals to pneumococcal infections.

Major companies in the pneumococcal vaccine market are actively innovating new products. For instance, Merck & Co Inc., a prominent pharmaceutical company, introduced the V116 vaccine in July 2023. Designed to target eight distinct serotypes of Streptococcus pneumoniae responsible for adult pneumococcal disease, V116 has exhibited superior immunogenicity compared to other vaccines in adult populations. Notably, the U.S. Food and Drug Administration (FDA) has designated V116 as a breakthrough therapy, currently advancing through Phase 3 development.

Conjugate vaccines are gaining prominence among major companies in the pneumococcal vaccine market, offering enhanced protection by targeting multiple serotypes. Pfizer, a leading pharmaceutical company, launched PREVNAR 20 in April 2023, a conjugate vaccine designed to protect against the 20 pneumococcal serotypes responsible for the majority of pneumococcal diseases. The development of such advanced vaccines underscores the commitment to comprehensive preventive measures.

In August 2022, GSK plc strategically acquired Affinivax, Inc., a clinical-stage biopharmaceutical company, for an undisclosed amount. This acquisition provides GSK plc with access to innovative technologies, including the Multiple Antigen Presenting System (MAPS), and the 24-valent pneumococcal vaccine candidate, further solidifying its position in the pneumococcal vaccine market.

Major companies operating in the pneumococcal vaccine market report are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Novartis International AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd., Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd., Biological E Limited, Hualan Biological Engineering Inc., Valneva SE, Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd., Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

North America was the largest region in the pneumococcal vaccine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pneumococcal vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pneumococcal vaccine market consists of sales of vaxneuvance, prevnar 20, pneumococcal conjugate vaccines (PCV)10, and pneumococcal conjugate vaccines (PCV)7. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pneumococcal Vaccine Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pneumococcal vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pneumococcal vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pneumococcal vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Product Type: Prevnar 13; Synflorix; Pneumovax23; Other Products
• 2) By Route of Administration: Intravenous; Intramuscular; Subcutaneous
• 3) By Distribution Channel: Pharmacies; Community Clinics; Public Health Agencies; Other Distribution Channels
• 4) By End User: Pediatrics; Adults
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; Novartis International AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pneumococcal Vaccine Market Characteristics

3. Pneumococcal Vaccine Market Trends And Strategies

4. Pneumococcal Vaccine Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Pneumococcal Vaccine Market Size and Growth

• 5.1. Global Pneumococcal Vaccine Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Pneumococcal Vaccine Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Pneumococcal Vaccine Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Pneumococcal Vaccine Market Segmentation

• 6.1. Global Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Prevnar 13
• Synflorix
• Pneumovax23
• Other Products
• 6.2. Global Pneumococcal Vaccine Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Intravenous
• Intramuscular
• Subcutaneous
• 6.3. Global Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Pharmacies
• Community Clinics
• Public Health Agencies
• Other Distribution Channels
• 6.4. Global Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Pediatrics
• Adults

7. Pneumococcal Vaccine Market Regional And Country Analysis

• 7.1. Global Pneumococcal Vaccine Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Pneumococcal Vaccine Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Pneumococcal Vaccine Market

• 8.1. Asia-Pacific Pneumococcal Vaccine Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Pneumococcal Vaccine Market

• 9.1. China Pneumococcal Vaccine Market Overview
• 9.2. China Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Pneumococcal Vaccine Market

• 10.1. India Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Pneumococcal Vaccine Market

• 11.1. Japan Pneumococcal Vaccine Market Overview
• 11.2. Japan Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Pneumococcal Vaccine Market

• 12.1. Australia Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Pneumococcal Vaccine Market

• 13.1. Indonesia Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Pneumococcal Vaccine Market

• 14.1. South Korea Pneumococcal Vaccine Market Overview
• 14.2. South Korea Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Pneumococcal Vaccine Market

• 15.1. Western Europe Pneumococcal Vaccine Market Overview
• 15.2. Western Europe Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Pneumococcal Vaccine Market

• 16.1. UK Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Pneumococcal Vaccine Market

• 17.1. Germany Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Pneumococcal Vaccine Market

• 18.1. France Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Pneumococcal Vaccine Market

• 19.1. Italy Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Pneumococcal Vaccine Market

• 20.1. Spain Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Pneumococcal Vaccine Market

• 21.1. Eastern Europe Pneumococcal Vaccine Market Overview
• 21.2. Eastern Europe Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Pneumococcal Vaccine Market

• 22.1. Russia Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Pneumococcal Vaccine Market

• 23.1. North America Pneumococcal Vaccine Market Overview
• 23.2. North America Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Pneumococcal Vaccine Market

• 24.1. USA Pneumococcal Vaccine Market Overview
• 24.2. USA Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Pneumococcal Vaccine Market

• 25.1. Canada Pneumococcal Vaccine Market Overview
• 25.2. Canada Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Pneumococcal Vaccine Market

• 26.1. South America Pneumococcal Vaccine Market Overview
• 26.2. South America Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Pneumococcal Vaccine Market

• 27.1. Brazil Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Pneumococcal Vaccine Market

• 28.1. Middle East Pneumococcal Vaccine Market Overview
• 28.2. Middle East Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Pneumococcal Vaccine Market

• 29.1. Africa Pneumococcal Vaccine Market Overview
• 29.2. Africa Pneumococcal Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Pneumococcal Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Pneumococcal Vaccine Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Pneumococcal Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Pneumococcal Vaccine Market Competitive Landscape
• 30.2. Pneumococcal Vaccine Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson & Johnson
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck & Co. Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Novartis International AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Sanofi S.A.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Pneumococcal Vaccine Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. GlaxoSmithKline plc
• 31.3. Eli Lilly and Company
• 31.4. Astellas Pharma Inc.
• 31.5. CSL Limited
• 31.6. Anhui Zhifei Longcom Biopharmaceutical Co. Ltd
• 31.7. Serum Institute of India Private Limited
• 31.8. Emergent BioSolutions Inc.
• 31.9. Walvax Biotechnology Co. Ltd
• 31.10. Biological E Limited
• 31.11. Hualan Biological Engineering Inc.
• 31.12. Valneva SE
• 31.13. Beijing Minhai Biotechnology Limited Company
• 31.14. NPO Petrovax Pharm LLC
• 31.15. Vaxcyte Inc.

32. Global Pneumococcal Vaccine Market Competitive Benchmarking

33. Global Pneumococcal Vaccine Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Pneumococcal Vaccine Market

35. Pneumococcal Vaccine Market Future Outlook and Potential Analysis

• 35.1 Pneumococcal Vaccine Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Pneumococcal Vaccine Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Pneumococcal Vaccine Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer